• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

GSK vaccine R&D head touts consistency of RSV data but is mum on restarting maternal trial

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Feb 16, 2023 at 10:22: AM
via GSK’s head of vaccine R&D, Phil Dormitzer, M.D., Ph.D., can almost taste regulatory success as the company soon approaches an FDA deadline for a decision on its respiratory syncytial virus (RSV) vaccine in older adults. If approved, it could become the first in the world.

article source
 




Top Bottom
Back
Quote